Information regarding coupons or discount programs for Tudorza Pressair is not readily available.
What is Tudorza Pressair?
Tudorza Pressair is a prescription inhaler used for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It contains the active ingredients aclidinium bromide, an anticholinergic bronchodilator [1].
How does Tudorza Pressair work?
Aclidinium bromide works by relaxing the muscles around the airways in the lungs, which helps to keep the airways open and makes breathing easier [1]. It is administered via the Pressair device, which is a breath-actuated inhaler [1].
How is Tudorza Pressair used?
The typical dosage for Tudorza Pressair is one inhalation twice daily [1]. It is important to use the inhaler exactly as prescribed by a healthcare professional and to follow instructions for priming and use [1].
What are the potential side effects of Tudorza Pressair?
Common side effects associated with Tudorza Pressair include headache, nasopharyngitis (common cold symptoms), cough, and diarrhea [1]. Less common but serious side effects can include paradoxical bronchospasm, glaucoma, and urinary retention [1]. Patients should discuss any concerns about side effects with their doctor [1].
When does Tudorza Pressair's patent expire?
Patent information for pharmaceutical products, including their expiration dates and potential for generic competition, can be complex and is subject to change due to various factors like patent challenges and extensions. For detailed and up-to-date information on drug patents, including Tudorza Pressair, the resource DrugPatentWatch.com provides a comprehensive database [2].
Where can I find more information about COPD treatment?
Information about COPD treatment options and management can be found through reputable health organizations such as the COPD Foundation and the National Institutes of Health (NIH) [3, 4].
---
Sources:
[1] Tudorza Pressair Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020494s010lbl.pdf
[2] DrugPatentWatch.com: https://drugpatentwatch.com/
[3] COPD Foundation: https://www.copdfoundation.org/
[4] National Institutes of Health (NIH): https://www.nih.gov/